All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
On May 25, 2023, quizartinib, an oral, highly potent and selective type II FLT3 inhibitor was approved by Japan’s Ministry of Health, Labour, and Welfare (MHLW) for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) with FLT3-internal tandem duplication (FLT3-ITD) mutations.1
This approval is for use in combination with standard cytarabine and anthracycline induction, standard cytarabine consolidation chemotherapy, and as maintenance monotherapy. Quizartinib is the first FLT3 inhibitor approved for newly diagnosed patients with AML in Japan, having received approval in 2019 as a monotherapy in the relapsed/refractory AML setting.1
This approval is based on the results from the randomized, double-blind, placebo-controlled, phase III QuANTUM-First trial (NCT02668653), which has been previously covered on the AML Hub. In this trial, the addition of quizartinib to standard cytarabine and anthracycline induction and standard cytarabine consolidation, and quizartinib maintenance monotherapy was associated with a 22.4% reduction in the risk of death when compared with standard chemotherapy alone (hazard ratio, 0.78; 95% confidence interval [CI], 0.62–0.98; p = 0.032).1 Median overall survival in the quizartinib arm (n = 268) was 31.9 months (95% CI, 21.0–NE) compared with 15.1 months (95% CI, 13.2–26.2) in the standard chemotherapy arm (n = 271).1 The most common adverse reactions in patients who received quizartinib were neutropenia (25.0%), thrombocytopenia (22.7%), nausea (20.6%), and electrocardiogram QT prolonged (19.3%), consistent with previous reports.1
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox